Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Phase 2 Trial to Evaluate Safety of a Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

NCT01903928 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01903928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01903928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Phase 2 Trial to Evaluate Safety of a Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
June 20, 2013
Completion date
January 19, 2015
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic cell transplant